Account wins from the 02/03 News Brief

Share this article:
PDI has entered a three-year agreement with Align Pharmaceuticals to assist the latter with the commercialization of its new product entries for the oncology market. PDI will initially provide a sales team of 40 field reps to oversee the sales of three oncology products recently acquired by Align. Two of the drugs, Numoisyn Lozenges and Numoisyn Liquid, were designed for xerostomia or dry mouth caused by radiation therapy, or Sjogren’s syndrome. Xclair, the third product, was approved to treat the symptoms of radiation dermatitis. The primary audience will be radiation oncologists, with additional calls made to select rheumatologists.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions